Update on Fillers Michael Gold, MD Recently, Dr Gold published an article on an International Perspective on Fillers. In Europe, Restylane is a very large family of products. It is made by a company called Q-Med who is now owned by Galderma. Before the merger, Q-Med licensed all of the products to Medicis (now owned […]
Kent Remington, MD Dr Remington began the filler session with a discussion on facial reflation and the concept of aesthetics. For many years, we focused on the old aesthetic rule of “if it ain’t broke, don’t fix it.” The new rule in aesthetics is “if it ain’t broke, break it, then fix it and make […]
What’s New? Are there differences? Michael Gold, MD New concepts and new information The global medical aesthetic market is expected to grow 10.8% per year between 2010 an 2015 and many other companies throughout the world are beginning to develop toxins. The clinical trials used to be FDA approved have changed since Botox was […]
Botulinum Toxin 2013: Where are we now? Joel Cohen, MD It is important that clinicians understand the molecular structure of Botulinum neurotoxin type A. Botox and Dysport have an envelope of protein around it; xeomin; however, does not have these accessory proteins. Differentiating Botulinum Toxins Regulatory agencies worldwide have recognized that these products are not […]
Comorbidities and Cardiovascular Status of Psoriasis Patients Craig Leonardi, MD In this final session of the psoriasis discussion, Dr Leonardi discussed co-morbidities and the cardiovascular status of patients with psoriasis. Metabolic Syndrome and Psoriasis Psoriasis patients are at an increased risk for the metabolic syndrome. There are meta-analyses that have been performed that have shown […]
Pipeline Psoriatic Arthritis Therapies that Have Efficacy in Psoriasis Arthur Kavanaugh, MD There are many potential therapies currently under development for the treatment of psoriatic arthritis (PsA) and appear to fall under two categories: biologic agents and oral agents (kinase/enzyme inhibitors). Th Cell Development Th17 cells are elevated in PsA patients. One of the exciting […]
Emerging Therapies Craig Leonardi, MD Dr Leonardi began this session with an update on what’s new in the first quarter of 2013 with regards to biologic therapy. So, where have we been? Our first set of drugs was T-cell inhibitors. This was a wonderful rationale, but since then these drugs have fallen by the wayside […]
Lawrence Eichenfield, MD Lots of new studies have been conducted with regards to pediatric acne along with some updates to The American Acne and Rosacea Society’s Pediatric Guidelines, which have also been recently endorsed by The American Academy of Pediatrics. For dermatologists, mid-childhood (age 1 – 7) acne is most worrisome. It can be associated […]
Our panel of experts in the field of Acne and Rosacea presented interesting case studies and new data that may help the practicing dermatologist improve the overall outcomes of patients in their practice. Isotretinoin Issues Guy Webster, MD, PhD What are the reasons that 20% of patients do not respond to isotretinoin? Inadequate dosing Virilization […]
Andrew Blauvelt, MD Dr Blauvelt presented an update on important information and data on infectious diseases that were published in some of the top tier medical journals in 2012 and their clinical implications for the practicing dermatologist. Clinical Pearls Look for Staph. Aureus infection in and around implantable electronic devices-these were associated with hematomas and […]
Administrative Office
Maui Derm
161 Wailea Ike Place, Suite A-104
Kihei, HI 96753
Stay Connected
Sign up to receive updates about upcoming meetings.